VAP Cholesterol test can help doctors and clinicians identify best
treatment options for patients at risk of heart disease
BIRMINGHAM, Ala., Jan. 31 /PRNewswire/ -- Clinical trial results from a new cholesterol-fighting drug combination point to the need for more detailed cholesterol testing, including direct measurement of LDL and other lipids. That's according to Atherotech, a cardio-diagnostic company that has developed an expanded cholesterol test called the VAP (Vertical Auto Profile) test, which can help doctors and clinicians identify the best treatment options for patients at risk of heart disease.
According to Atherotech Chief Medical Officer James Ehrlich, M.D., media reports about recently released trials have now resulted in widespread concern and confusion about the general value of lipid lowering agents, particularly statins, which play a critically important role in very high risk patients. Ehrlich pointed to a recent BusinessWeek article that raised multiple questions about the role of statins in the prevention of coronary disease, the nation's top killer.
"Atherotech believes that precise physician decisions about lifelong management of hypercholesterolemia can only be accomplished with a detailed profiling of lipoprotein components," said Atherotech Chief Medical Officer James Ehrlich, M.D. "By identifying the patient's true risk and by detailing his/her lipid profile with a VAP test, the physician can now successfully modify risk and improve the lipid levels in a rational manner. Some patients need combination therapy while others are well treated with monotherapy (statins)."
Ehrlich explained that new drugs and therapies are still important
tools in helping individuals at risk to reach LDL goals, sometimes without
statin therapy. However, he emphasized how we modify lipoprotein patterns
may be more important in decreasing the risk of heart attack and stroke
than simply lowering LDL cholesterol alone
|SOURCE Atherotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved